Top Markets
Coin of the day
ABVC BioPharma, Inc. ABVC BioPharma, Inc.

ABVC BioPharma, Inc.

ABVC
Rangering i aksjer #28871
ABVC BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on... ABVC BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on creating novel drugs and medical devices to address critical, underserved healthcare requirements across the United States. The company's pipeline includes several key candidates: ABV-1501, currently undergoing Phase I/II clinical trials, is being developed as a combination treatment for triple-negative breast cancer. ABV-1504 has successfully completed Phase II clinical trials for major depressive disorders. ABV-1505 is progressing through Phase II clinical studies for attention deficit hyperactivity disorder (ADHD). ABV-1703 has concluded its Phase I clinical trials for the treatment of pancreatic cancer. ABV-1702 has also finished Phase I clinical investigations for myelodysplastic syndromes. ABV-1601 is in Phase I/II clinical trials, aimed at alleviating depression in individuals with cancer. ABV-1701 Vitargus is in development to treat conditions such as retinal detachment or vitreous hemorrhage. ABVC BioPharma maintains strategic alliances, including a co-development arrangement with Rgene Corporation, alongside collaborative agreements with BioHopeKing Corporation and BioFirst Corporation. The company's headquarters are located in Fremont, California, and it operates as a subsidiary of YuanGene Corporation.
Aksjekurs
$0.93
Markedsverdi
$24.18M
Endring (1 dag)
7.38%
Endring (1 år)
-67.37%
Land
US
Handel ABVC BioPharma, Inc. (ABVC)

Kategori

EPS for ABVC BioPharma, Inc. (ABVC)
EPS per 2026 TTM: 0
Ifølge de siste økonomiske rapportene og aksjekursen til ABVC BioPharma, Inc. er selskapets nåværende EPS (TTM) 0. Ved slutten av 2026 hadde selskapet en EPS på 0, lik EPS-en i 2026 som var 0.
EPS-historikk for ABVC BioPharma, Inc. fra 2026 til 2026
EPS ved slutten av hvert år
År EPS Endre
Ikke nok data for de angitte datoene.
EPS for lignende selskaper eller konkurrenter
Selskap EPS EPS-forskjell Land
$17.32 -
US
$27.74 -
NL
$-7.98 -
US
$2.98 -
AU
- -
CH